HK1132176A1 - Stabilized ophthalmic compositions comprising oxidatively unstable components - Google Patents

Stabilized ophthalmic compositions comprising oxidatively unstable components

Info

Publication number
HK1132176A1
HK1132176A1 HK09108411.5A HK09108411A HK1132176A1 HK 1132176 A1 HK1132176 A1 HK 1132176A1 HK 09108411 A HK09108411 A HK 09108411A HK 1132176 A1 HK1132176 A1 HK 1132176A1
Authority
HK
Hong Kong
Prior art keywords
ophthalmic compositions
unstable components
oxidatively unstable
stabilized ophthalmic
stabilized
Prior art date
Application number
HK09108411.5A
Other languages
English (en)
Chinese (zh)
Inventor
Shivkumar Mahadevan
Frank Molock
Original Assignee
Johnson & Johnson Vision Care
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johnson & Johnson Vision Care filed Critical Johnson & Johnson Vision Care
Publication of HK1132176A1 publication Critical patent/HK1132176A1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK09108411.5A 2006-03-17 2009-09-14 Stabilized ophthalmic compositions comprising oxidatively unstable components HK1132176A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78355706P 2006-03-17 2006-03-17
PCT/US2007/064142 WO2007109523A2 (en) 2006-03-17 2007-03-16 Stabilized ophthalmic compositions comprising oxidatively unstable components

Publications (1)

Publication Number Publication Date
HK1132176A1 true HK1132176A1 (en) 2010-02-19

Family

ID=38421691

Family Applications (2)

Application Number Title Priority Date Filing Date
HK09105622.6A HK1127998A1 (zh) 2006-03-17 2009-06-23 含有氧化不穩定組分的穩定的眼用組合物
HK09108411.5A HK1132176A1 (en) 2006-03-17 2009-09-14 Stabilized ophthalmic compositions comprising oxidatively unstable components

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HK09105622.6A HK1127998A1 (zh) 2006-03-17 2009-06-23 含有氧化不穩定組分的穩定的眼用組合物

Country Status (13)

Country Link
US (4) US8466174B2 (xx)
EP (1) EP2010143B1 (xx)
JP (1) JP5275214B2 (xx)
KR (3) KR20140083056A (xx)
CN (1) CN101420934B (xx)
AR (1) AR059927A1 (xx)
AU (1) AU2007227091B2 (xx)
BR (1) BRPI0709549A2 (xx)
CA (2) CA2908828C (xx)
HK (2) HK1127998A1 (xx)
RU (2) RU2462234C2 (xx)
TW (1) TWI454286B (xx)
WO (1) WO2007109523A2 (xx)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2648115C (en) * 2006-03-31 2015-03-24 Vistakon Pharmaceuticals, Llc Ocular allergy treatments
SG177934A1 (en) 2006-09-29 2012-02-28 Johnson & Johnson Vision Care Methods and ophthalmic devices used in the treatment of ocular allergies
US20090239954A1 (en) * 2008-03-19 2009-09-24 Collins Gary L Phosphate buffered ophthalmic solutions displaying improved efficacy
US20100226999A1 (en) * 2009-03-06 2010-09-09 Tracy Quevillon-Coleman Process for forming stabilized ophthalmic solutions
IT1393419B1 (it) * 2009-03-19 2012-04-20 Medivis S R L Composizioni oftalmiche a base di acidi grassi polinsaturi omega-3 e omega-6.
JP5675183B2 (ja) * 2009-06-16 2015-02-25 ロート製薬株式会社 水性組成物
US20120225918A1 (en) 2011-03-03 2012-09-06 Voom, Llc Compositions and Methods for Non-Surgical Treatment of Ptosis
TWI713618B (zh) * 2015-10-29 2020-12-21 日商帝化製藥股份有限公司 外用劑
CA3093371A1 (en) 2018-03-09 2019-09-12 Portola Pharmaceuticals, Inc. Methods of use and pharmaceutical compositions of a selective syk inhibitor
US10799481B1 (en) 2019-05-06 2020-10-13 Rvl Pharmaceuticals, Inc. Compositions and methods for treating ocular disorders

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4304762A (en) * 1978-09-27 1981-12-08 Lever Brothers Company Stabilization of hydrogen peroxide
DD150694A1 (de) * 1980-04-16 1981-09-16 Gisela Raether Verfahren zur stabilisierung von pharmazeutischen praeparaten mit oxidationsempfindlichen bestandteilen
DE3640708C2 (de) * 1986-11-28 1995-05-18 Schering Ag Verbesserte metallhaltige Pharmazeutika
DE68929516T2 (de) * 1988-08-04 2005-01-05 Novartis Ag Verfahren zur Konservierung ophthalmischer Lösungen und Zusammensetzungen dafür
US5514732A (en) * 1993-07-22 1996-05-07 Johnson & Johnson Vision Products, Inc. Anti-bacterial, insoluble, metal-chelating polymers
AU1716995A (en) 1994-03-18 1995-10-09 Ciba-Geigy Ag Aqueous solution of levocabastine for ophthalmic use
JPH07324034A (ja) 1994-05-30 1995-12-12 Toa Yakuhin Kk フマル酸ケトチフェン含有の点眼剤
US5683993A (en) * 1995-06-22 1997-11-04 Ciba Vision Corporation Compositions and methods for stabilizing polymers
US6020373A (en) * 1995-10-20 2000-02-01 Eastern Virginia Medical School Chelate derivatives as protectors against tissue injury
RU2140236C1 (ru) * 1996-08-20 1999-10-27 Хабаровский филиал МНТК "Микрохирургия глаза" Способ лечения диабетической ретинопатии
AR002194A1 (es) * 1997-03-17 1998-01-07 Sanchez Reynaldo Alemany Instrumento computarizado para el analisis del movimiento.
US5980882A (en) * 1997-04-16 1999-11-09 Medeva Pharmaceuticals Manufacturing Drug-resin complexes stabilized by chelating agents
JPH11189528A (ja) * 1997-12-26 1999-07-13 Lead Chemical Co Ltd 安定性の改善された皮膚適用製剤
EP0938896A1 (en) * 1998-01-15 1999-09-01 Novartis AG Autoclavable pharmaceutical compositions containing a chelating agent
JPH11279205A (ja) * 1998-03-26 1999-10-12 Nippon Tenganyaku Kenkyusho:Kk ヒアルロン酸類製剤の分解抑制方法
ATE269079T1 (de) 1998-04-02 2004-07-15 Novartis Pharma Gmbh Stabilisierung pharmazeutischer zusammensetzungen durch besonderen einsatz eines antioxidans
WO2000003705A1 (en) 1998-07-14 2000-01-27 Alcon Laboratories, Inc. Use of 11-(3-dimethylaminopropylidene)-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid for the manufacture of a medicament for treating non-allergic ophthalmic inflammatory disorders and for the prevention of ocular neovascularization
US6395756B2 (en) 1999-12-23 2002-05-28 Novartis Ag Use of ophthalmic agent
RU2196594C2 (ru) * 2000-09-25 2003-01-20 Общество с ограниченной ответственностью "Камелия НПП" Средство, обладающее восстановительным, тонизирующим и регенераторным действием
WO2002026277A2 (en) 2000-09-28 2002-04-04 Novartis Ag Stabilized hydrogen peroxide solutions
TW586946B (en) * 2000-12-22 2004-05-11 Novartis Ag Process to improve stability
RU2191012C1 (ru) * 2001-06-20 2002-10-20 Научно-исследовательский испытательный центр (медико-биологической защиты) Государственного научно-исследовательского испытательного института военной медицины МО РФ Глазные капли для лечения эндотелиально-эпителиальной дистрофии роговицы
RU2201213C1 (ru) * 2001-07-04 2003-03-27 Общество с ограниченной ответственностью "Научно-экспериментальное производство Микрохирургия глаза" Глазные капли "карнозин"
JP4436131B2 (ja) * 2001-11-21 2010-03-24 イオルテク ヒアルロン酸を安定化させる組成物
US20070092582A1 (en) * 2002-01-18 2007-04-26 Fu-Pao Tsao Methods of preserving ophthalmic solutions and preserved ophthalmic solutions
AU2003297511B2 (en) * 2002-12-20 2010-01-21 Chakshu Research, Inc. Ophthalmic formulation for the prevention and treatment of ocular conditions
US20050244509A1 (en) * 2004-03-17 2005-11-03 Fu-Pao Tsao Ophthalmic solutions
US20070077303A1 (en) * 2005-09-30 2007-04-05 Azaam Alli Methods for providing oxidatively stable ophthalmic compositions
SG177934A1 (en) * 2006-09-29 2012-02-28 Johnson & Johnson Vision Care Methods and ophthalmic devices used in the treatment of ocular allergies

Also Published As

Publication number Publication date
CA2646424C (en) 2015-12-29
CA2908828A1 (en) 2007-09-27
HK1127998A1 (zh) 2009-10-16
TWI454286B (zh) 2014-10-01
CN101420934A (zh) 2009-04-29
WO2007109523A3 (en) 2008-04-10
CA2646424A1 (en) 2007-09-27
AR059927A1 (es) 2008-05-07
EP2010143B1 (en) 2015-08-12
AU2007227091A1 (en) 2007-09-27
AU2007227091B2 (en) 2013-02-07
KR101454674B1 (ko) 2014-10-27
KR20150017002A (ko) 2015-02-13
US20180050026A1 (en) 2018-02-22
RU2462234C2 (ru) 2012-09-27
US8466174B2 (en) 2013-06-18
WO2007109523A2 (en) 2007-09-27
US9474746B2 (en) 2016-10-25
US20070265234A1 (en) 2007-11-15
CN101420934B (zh) 2014-03-19
JP5275214B2 (ja) 2013-08-28
KR20080111065A (ko) 2008-12-22
US20140011843A1 (en) 2014-01-09
JP2009530314A (ja) 2009-08-27
US20170007592A1 (en) 2017-01-12
RU2008141172A (ru) 2010-04-27
RU2012125612A (ru) 2013-12-27
TW200808355A (en) 2008-02-16
KR20140083056A (ko) 2014-07-03
CA2908828C (en) 2018-01-16
BRPI0709549A2 (pt) 2011-07-19
EP2010143A2 (en) 2009-01-07

Similar Documents

Publication Publication Date Title
HUS2000015I1 (hu) Fungicid készítmények
HK1132176A1 (en) Stabilized ophthalmic compositions comprising oxidatively unstable components
ZA200808773B (en) Stable emulsion formulations
EP2040708A4 (en) CROSS-CONTAINING COMPOSITIONS
EP2124575A4 (en) ANTIMICROBIAL COMPOSITIONS
HK1121925A1 (en) Tobacco compositions
GB0621023D0 (en) Fragrance compositions
HK1134245A1 (en) Multiple emulsion compositions
IL243457B (en) Cyclopropane preparations
GB0625069D0 (en) Compositions
GB0501192D0 (en) Stable prostaglandin-containing compositions
ZA200710193B (en) Stable emulsion composition
GB0620279D0 (en) Compositions
IL197927A0 (en) W/o/w emulsion composition
GB0615213D0 (en) Fungicidal compounds and compositions
GB0618657D0 (en) Compositions
EP1986849A4 (en) COMBUSTION REMOVAL COMPOSITIONS, RESISTANT TO WASH
GB0615583D0 (en) Perfume compositions
GB0621020D0 (en) Fragrance compositions
GB0615580D0 (en) Perfume compositions
SG131101A1 (en) Methods for providing oxidatively stable ophthalmic compositions
EP1894565A4 (en) STABILIZED MILNACIPRANE FORMULATION
PT1865051T (pt) Composições de branqueamento
GB0620918D0 (en) Compositions
EP2061445A4 (en) ANTIMICROBIAL COMPOSITIONS